HUYA Bioscience International Further Strengthens Executive Team

SAN DIEGO, March 12, 2015 /PRNewswire/ -- HUYA Bioscience International (HUYA) today announced a key addition to its Executive Team. Alain Rolland, Pharm.D., Ph.D., has been appointed as Executive Vice President and Chief Scientific Officer.

Dr. Rolland brings 25 years of international leadership experience in the biopharma industry, including positions at Ciba-Geigy, Galderma, GeneMedicine, Valentis, and Vical.

"I am delighted to welcome Alain to the HUYA Executive Team, where he joins Mr. John Sharp, CPA, Chief Financial Officer and Mr. Clem Gingras, Chief Technology Officer & Chief Operating Officer, Asia," said Mireille Gillings Ph.D., CEO of HUYA.

Mr. Sharp's career in finance has spanned over 20 years, with extensive public company experience and a biopharma focus, and employers including Ligand Pharmaceuticals, where he played a key role in multiple acquisitions and in the company's restructure and transition to profitability. Mr. Gingras has 18 years of management and operational experience with international brands; he is responsible for HUYA's growth and operations in China and Japan, and directs the company's IT and technology development.

"Alain, Clem and John's years of broad healthcare industry and operational experience will be essential as HUYA's programs advance and our company moves towards its next phase of growth," said Dr. Gillings.

Most recently, Dr. Rolland was a Corporate Officer and Executive Vice President of Product Development at Vical, a biopharma R&D company developing cancer immunotherapeutics and infectious disease vaccines. He has a Pharm.D. and a Ph.D. in Pharmaceutical Sciences from Rennes University, France.

About HUYA Bioscience International
HUYA Bioscience International is a leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the US, Japan and in eight strategic locations across China, with joint headquarters in San Diego and Shanghai. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally.

www.huyabio.com

Contact details:
Jill Dawson, Ph.D.
Corporate Communications
HUYA Bioscience International
+1.919.360.8704
[email protected]

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.